Cargando…

Why Is There No Cure for Tinnitus?

Tinnitus is unusual for such a common symptom in that there are few treatment options and those that are available are aimed at reducing the impact rather than specifically addressing the tinnitus percept. In particular, there is no drug recommended specifically for the management of tinnitus. Whils...

Descripción completa

Detalles Bibliográficos
Autores principales: McFerran, Don J., Stockdale, David, Holme, Ralph, Large, Charles H., Baguley, David M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691100/
https://www.ncbi.nlm.nih.gov/pubmed/31447630
http://dx.doi.org/10.3389/fnins.2019.00802
_version_ 1783443293772709888
author McFerran, Don J.
Stockdale, David
Holme, Ralph
Large, Charles H.
Baguley, David M
author_facet McFerran, Don J.
Stockdale, David
Holme, Ralph
Large, Charles H.
Baguley, David M
author_sort McFerran, Don J.
collection PubMed
description Tinnitus is unusual for such a common symptom in that there are few treatment options and those that are available are aimed at reducing the impact rather than specifically addressing the tinnitus percept. In particular, there is no drug recommended specifically for the management of tinnitus. Whilst some of the currently available interventions are effective at improving quality of life and reducing tinnitus-associated psychological distress, most show little if any effect on the primary symptom of subjective tinnitus loudness. Studies of the delivery of tinnitus services have demonstrated considerable end-user dissatisfaction and a marked disconnect between the aims of healthcare providers and those of tinnitus patients: patients want their tinnitus loudness reduced and would prefer a pharmacological solution over other modalities. Several studies have shown that tinnitus confers a significant financial burden on healthcare systems and an even greater economic impact on society as a whole. Market research has demonstrated a strong commercial opportunity for an effective pharmacological treatment for tinnitus, but the amount of tinnitus research and financial investment is small compared to other chronic health conditions. There is no single reason for this situation, but rather a series of impediments: tinnitus prevalence is unclear with published figures varying from 5.1 to 42.7%; there is a lack of a clear tinnitus definition and there are multiple subtypes of tinnitus, potentially requiring different treatments; there is a dearth of biomarkers and objective measures for tinnitus; treatment research is associated with a very large placebo effect; the pathophysiology of tinnitus is unclear; animal models are available but research in animals frequently fails to correlate with human studies; there is no clear definition of what constitutes meaningful change or “cure”; the pharmaceutical industry cannot see a clear pathway to distribute their products as many tinnitus clinicians are non-prescribing audiologists. To try and clarify this situation, highlight important areas for research and prevent wasteful duplication of effort, the British Tinnitus Association (BTA) has developed a Map of Tinnitus. This is a repository of evidence-based tinnitus knowledge, designed to be free to access, intuitive, easy to use, adaptable and expandable.
format Online
Article
Text
id pubmed-6691100
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-66911002019-08-23 Why Is There No Cure for Tinnitus? McFerran, Don J. Stockdale, David Holme, Ralph Large, Charles H. Baguley, David M Front Neurosci Neuroscience Tinnitus is unusual for such a common symptom in that there are few treatment options and those that are available are aimed at reducing the impact rather than specifically addressing the tinnitus percept. In particular, there is no drug recommended specifically for the management of tinnitus. Whilst some of the currently available interventions are effective at improving quality of life and reducing tinnitus-associated psychological distress, most show little if any effect on the primary symptom of subjective tinnitus loudness. Studies of the delivery of tinnitus services have demonstrated considerable end-user dissatisfaction and a marked disconnect between the aims of healthcare providers and those of tinnitus patients: patients want their tinnitus loudness reduced and would prefer a pharmacological solution over other modalities. Several studies have shown that tinnitus confers a significant financial burden on healthcare systems and an even greater economic impact on society as a whole. Market research has demonstrated a strong commercial opportunity for an effective pharmacological treatment for tinnitus, but the amount of tinnitus research and financial investment is small compared to other chronic health conditions. There is no single reason for this situation, but rather a series of impediments: tinnitus prevalence is unclear with published figures varying from 5.1 to 42.7%; there is a lack of a clear tinnitus definition and there are multiple subtypes of tinnitus, potentially requiring different treatments; there is a dearth of biomarkers and objective measures for tinnitus; treatment research is associated with a very large placebo effect; the pathophysiology of tinnitus is unclear; animal models are available but research in animals frequently fails to correlate with human studies; there is no clear definition of what constitutes meaningful change or “cure”; the pharmaceutical industry cannot see a clear pathway to distribute their products as many tinnitus clinicians are non-prescribing audiologists. To try and clarify this situation, highlight important areas for research and prevent wasteful duplication of effort, the British Tinnitus Association (BTA) has developed a Map of Tinnitus. This is a repository of evidence-based tinnitus knowledge, designed to be free to access, intuitive, easy to use, adaptable and expandable. Frontiers Media S.A. 2019-08-06 /pmc/articles/PMC6691100/ /pubmed/31447630 http://dx.doi.org/10.3389/fnins.2019.00802 Text en Copyright © 2019 McFerran, Stockdale, Holme, Large and Baguley. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
McFerran, Don J.
Stockdale, David
Holme, Ralph
Large, Charles H.
Baguley, David M
Why Is There No Cure for Tinnitus?
title Why Is There No Cure for Tinnitus?
title_full Why Is There No Cure for Tinnitus?
title_fullStr Why Is There No Cure for Tinnitus?
title_full_unstemmed Why Is There No Cure for Tinnitus?
title_short Why Is There No Cure for Tinnitus?
title_sort why is there no cure for tinnitus?
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691100/
https://www.ncbi.nlm.nih.gov/pubmed/31447630
http://dx.doi.org/10.3389/fnins.2019.00802
work_keys_str_mv AT mcferrandonj whyistherenocurefortinnitus
AT stockdaledavid whyistherenocurefortinnitus
AT holmeralph whyistherenocurefortinnitus
AT largecharlesh whyistherenocurefortinnitus
AT baguleydavidm whyistherenocurefortinnitus